Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors

Ayala Pharmaceuticals, Inc. has successfully concluded an End-of-Phase 2 meeting with the FDA regarding AL102, a potential treatment for desmoid tumors. The company confirms agreement with the FDA on key elements of the Phase 3 segment of the ongoing RINGSIDE study, including the dosing regimen. Enrollment in Phase 3 is continuing as planned. Desmoid tumors are rare connective tissue tumors that..